Feasibility and Consistency of Results with Deployment of an In-Line Filter for Exercise-Based Evaluations of Patients With Heart Failure During the Novel Coronavirus Disease-2019 Pandemic

Abstract Funding Acknowledgements Type of funding sources: None. Background The COVID-19 outbreak has presented significant challenges for healthcare systems worldwide, which are responsible for guaranteeing access to care for all patients and limiting the spread of the virus. The necessary changes in the healthcare systems have deeply impacted not only people affected by the novel coronavirus, but also those with chronic conditions, such as heart failure. Since the beginning of the pandemic, a reduction of routine visits and use of emergency services by patients with heart failure has been observed, and these patients have tended to visit the hospital only when their symptoms were severe. The consequences of the COVID-19 pandemic on heart failure patients’ lives have not yet been investigated. Purpose To explore the lived experiences of patients with heart failure during the COVID-19 pandemic. Methods A qualitative investigation based on interpretative phenomenological analysis was conducted. Fourteen patients with heart failure (12 males and 2 females with a median age of 68 years) completed in-depth, semi-structured interviews. Triangulation, journaling and member checking were used to improve the rigour of the study. Results Three themes describing the lived experience of patients were identified: "being vulnerable", "hanging in the balance", and "coping strategies". Patients reported feeling particularly vulnerable to the novel coronavirus due to their clinical conditions, and therefore they experienced fear and anxiety. Changes in the healthcare systems due to the COVID-19 pandemic created a sense of uncertainty that patients described as a feeling of hanging in the balance. However, despite these relevant difficulties, heart failure patients have managed to deal with the situation using various coping strategies, such as acceptance, recreational activities, family reorganization, and use of technology. Conclusions The COVID-19 outbreak deeply affected the lives of patients with heart failure, and our results highlight the relevant difficulties they have faced. We point out that there is a great need for targeted interventions, and these could be developed taking into consideration the coping strategies described in the study.

Download Full-text

Tolvaptan, the Novel Medicine to Optimize Serum Sodium Concentrations in Patients with Heart Failure

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2013.08.418 ◽

2013 ◽

Vol 19 (10) ◽

pp. S160

Author(s):

Masatake Kobayashi ◽

Kunihiko Teraoka ◽

Yoichi Iwasaki ◽

Yuto Kumai ◽

Mamoru Aiga ◽

...

Keyword(s):

Heart Failure ◽

Serum Sodium ◽

The Novel ◽

Patients With Heart Failure

Download Full-text

The Novel Use of Mitraclip in a Patient with Combined Multiple Myeloma and Heart Failure with Severe Mitral Regurgitation

Austin Cardio & Cardiovascular Case Reports ◽

10.26420/austincardiocardiovasccaserep.2021.1039 ◽

2021 ◽

Vol 6 (1) ◽

Author(s):

Abu Ghosh Z ◽

◽

Beeri R ◽

Falah B ◽

Pertz A ◽

...

Keyword(s):

Heart Failure ◽

Multiple Myeloma ◽

Mitral Valve ◽

Mitral Regurgitation ◽

Mitral Valve Repair ◽

Severe Mitral Regurgitation ◽

The Novel ◽

Valve Repair ◽

Oncological Treatment ◽

Patients With Heart Failure

Oncology patients with Heart Failure (HF) and severe Mitral Regurgitation (MR) are often considered to have a prohibitive risk for surgical mitral valve repair/replacement. We describe a patient with active multiple myeloma and significant HF and MR who was treated with MitraClip, which improved symptoms and allowed delivery of optimal oncological treatment.

Download Full-text

The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19

Diagnostics ◽

10.3390/diagnostics11020175 ◽

2021 ◽

Vol 11 (2) ◽

pp. 175

Author(s):

Radu-Stefan Miftode ◽

Antoniu Octavian Petriș ◽

Viviana Onofrei Aursulesei ◽

Corina Cianga ◽

Irina-Iuliana Costache ◽

...

Keyword(s):

Heart Failure ◽

Myocardial Injury ◽

Clinical Manifestations ◽

The Novel ◽

Inflammatory Biomarker ◽

Diagnosis And Prognosis ◽

Cardiovascular Comorbidities ◽

Patients With Heart Failure ◽

Cardioprotective Effects

The increasing incidence of coronavirus disease 19 (COVID-19) and its polymorphic clinical manifestations due to local and systemic inflammation represent a high burden for many public health systems. Multiple evidence revealed the interdependence between the presence of cardiovascular comorbidities and a severe course of COVID-19, with heart failure (HF) being incriminated as an independent predictor of mortality. Suppression of tumorigenicity-2 ST2 has emerged as one of the most promising biomarkers in assessing the evolution and prognosis of patients with HF. The uniqueness of ST2 is determined by its structural particularities. Its transmembrane isoform exerts cardioprotective effects, while the soluble isoform (sST2), which is detectable in serum, is associated with myocardial fibrosis and poor outcome in patients with HF. Some recent data also suggested the potential role of sST2 as a marker of inflammation, while other studies highlighted it as a valuable prognostic factor in patients with COVID-19. In this review, we summarized the pathways by which sST2 is related to myocardial injury and its connection to the severity of inflammation in patients with COVID-19. Also, we reviewed possible perspectives of using it as a dual cardio-inflammatory biomarker, for both early diagnosis, risk stratification and prognosis assessment of patients with concomitant HF and COVID-19.

Download Full-text

Cardiorespiratory complications in pediatric oncology patients with COVID-19 infection

10.22541/au.161670421.11574183/v1 ◽

2021 ◽

Author(s):

Peter Schoettler ◽

Paul Sue ◽

Tamra Slone ◽

Andrew Koh

Keyword(s):

Risk Factors ◽

Heart Failure ◽

Respiratory Failure ◽

Cancer Therapy ◽

Cardiac Function ◽

Pediatric Oncology ◽

The Novel ◽

Oncology Patients ◽

Novel Coronavirus ◽

Active Cancer

The risk of the novel coronavirus disease 2019 (COVID-19) to pediatric oncology patients is unknown. Here, we report eight pediatric oncology patients receiving active cancer therapy that tested positive for COVID-19. Three developed severe cardiorespiratory symptoms (as defined by evidence of heart failure by echocardiogram and/or intubation secondary to respiratory failure), including one death as a result of COVID-19 infection. We identified prior anthracycline exposure and pre-COVID cardiac function as significantly associated with the development of severe cardiorespiratory complications. These data merit future and further investigation of risk factors for severe complications related to COVID-19 infections in pediatric oncology patients.

Download Full-text

Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure

Biochemical and Biophysical Research Communications ◽

10.1016/s0006-291x(03)01424-4 ◽

2003 ◽

Vol 308 (3) ◽

pp. 480-485 ◽

Cited By ~ 172

Author(s):

Gábor Földes ◽

Ferenc Horkay ◽

István Szokodi ◽

Olli Vuolteenaho ◽

Mika Ilves ◽

...

Keyword(s):

Heart Failure ◽

Orphan Receptor ◽

The Novel ◽

Patients With Heart Failure

Download Full-text

Left Ventricular Assist Device Implantation to a Child with End Stage Heart Failure In The Novel Coronavirus Pandemic Period

10.21203/rs.3.rs-27337/v1 ◽

2020 ◽

Author(s):

Tanıl Özer ◽

Deniz Günay ◽

Mehmet Aksüt ◽

Özge Altaş ◽

Emre Gürcü ◽

...

Keyword(s):

Heart Failure ◽

Left Ventricular Assist Device ◽

Left Ventricular ◽

The Novel ◽

Assist Device ◽

Ventricular Assist ◽

Left Ventricular Assist ◽

End Stage Heart Failure ◽

Novel Coronavirus ◽

End Stage

Abstract At the end of the 2019, a novel coronavirus disease (COVID-19) appeared in Wuhan, China and spread rapidly to all over the world. Then, the attentions of almost all health care providers have shifted to this health emergency situation which is identified as pandemic. The novel coronavirus pandemic has impacted the physicians at the all field of medicine not to perform their routine treatment practice. Since it is not clear when this situation will end, there is still debate about how to manage the treatment strategies for the patients who have end stage heart failure such another life threatening illness. The aim of this case presentation is to create a consideration about timing of left ventricular assist device implantations during novel coronavirus pandemic period.

Download Full-text

Mechanism of Blood–Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury

International Journal of Molecular Sciences ◽

10.3390/ijms222413546 ◽

2021 ◽

Vol 22 (24) ◽

pp. 13546

Author(s):

Rubens P. Homme ◽

Akash K. George ◽

Mahavir Singh ◽

Irina Smolenkova ◽

Yuting Zheng ◽

...

Keyword(s):

Heart Failure ◽

Human Subjects ◽

Viral Myocarditis ◽

Vena Cava ◽

The Novel ◽

Barrier Dysfunction ◽

Novel Coronavirus ◽

Cardiac Manifestations ◽

Endocardial Endothelium ◽

Metalloproteinase 9

Although blood–heart-barrier (BHB) leakage is the hallmark of congestive (cardio-pulmonary) heart failure (CHF), the primary cause of death in elderly, and during viral myocarditis resulting from the novel coronavirus variants such as the severe acute respiratory syndrome novel corona virus 2 (SARS-CoV-2) known as COVID-19, the mechanism is unclear. The goal of this project is to determine the mechanism of the BHB in CHF. Endocardial endothelium (EE) is the BHB against leakage of blood from endocardium to the interstitium; however, this BHB is broken during CHF. Previous studies from our laboratory, and others have shown a robust activation of matrix metalloproteinase-9 (MMP-9) during CHF. MMP-9 degrades the connexins leading to EE dysfunction. We demonstrated juxtacrine coupling of EE with myocyte and mitochondria (Mito) but how it works still remains at large. To test whether activation of MMP-9 causes EE barrier dysfunction, we hypothesized that if that were the case then treatment with hydroxychloroquine (HCQ) could, in fact, inhibit MMP-9, and thus preserve the EE barrier/juxtacrine signaling, and synchronous endothelial-myocyte coupling. To determine this, CHF was created by aorta-vena cava fistula (AVF) employing the mouse as a model system. The sham, and AVF mice were treated with HCQ. Cardiac hypertrophy, tissue remodeling-induced mitochondrial-myocyte, and endothelial-myocyte contractions were measured. Microvascular leakage was measured using FITC-albumin conjugate. The cardiac function was measured by echocardiography (Echo). Results suggest that MMP-9 activation, endocardial endothelial leakage, endothelial-myocyte (E-M) uncoupling, dyssynchronous mitochondrial fusion-fission (Mfn2/Drp1 ratio), and mito-myocyte uncoupling in the AVF heart failure were found to be rampant; however, treatment with HCQ successfully mitigated some of the deleterious cardiac alterations during CHF. The findings have direct relevance to the gamut of cardiac manifestations, and the resultant phenotypes arising from the ongoing complications of COVID-19 in human subjects.

Download Full-text